Immutep has reported mature overall survival data from the investigator‑initiated INSIGHT‑003 trial that it says offer a hopeful signal for eftilagimod alfa, known as efti, in first-line non‑squamous non‑small cell lung cancer (NSCLC). …
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News -
US announces formal plan that benchmarks pricing against Australia and 18 other countries
October 1, 2026 - -
Sandoz leads pharma's best workplaces as Rare Cancers Australia makes healthcare list
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News